TOP STORIES

J&J's Tecvayli-Darzalex Gains Second-Line Myeloma Approval — CAR-T Therapies Face Direct Competition

Johnson & Johnson secured FDA approval on March 5 for Tecvayli-Darzalex (teclistamab plus daratumumab hyaluronidase-fihj) in relapsed/refractory multiple myeloma after at least one prior therapy, marking the third approval under the National Priority Voucher Program. The review took just 55 days from filing, per Pharmaceutical Commerce. Phase 3 MajesTEC-3 data showed an 83% reduction in risk of disease progression or death versus standard regimens (HR 0.17; 95% CI 0.12-0.23), with a three-year PFS rate of 83%, 89% ORR, and 58.4% MRD-negativity versus 17.1% in the control arm. The approval also converts teclistamab monotherapy from accelerated to traditional (full) approval in later-line myeloma. Over 23,000 patients have been treated with Tecvayli worldwide since its initial 2022 approval (Healio).

Competitive implications: Bristol Myers Squibb's Abecma (idecabtagene vicleucel) and J&J/Legend's own Carvykti (ciltacabtagene autoleucel)—both BCMA-targeted CAR-T therapies approved in myeloma—face intensified competition from an off-the-shelf bispecific that avoids the manufacturing delays and lymphodepletion conditioning inherent to cellular therapy. The 89% ORR and 83% three-year PFS may accelerate payer pressure on CAR-T pricing, particularly in community oncology settings without cell therapy infrastructure. Pfizer's bispecific elranatamab and Regeneron's linvoseltamab must now demonstrate differentiation against an approved second-line bispecific standard with mature survival data. J&J's press release described the approval as addressing patients who experience disease relapse, a population it characterized as representing a significant unmet need in myeloma treatment.

Key risks: J&J's combination faces adoption challenges if physicians remain committed to CAR-T sequencing based on long-term remission data that bispecifics have yet to match. Manufacturing constraints for daratumumab could limit commercial momentum if demand exceeds supply projections.

Moderna Pays $2.25B to Settle LNP Patent Disputes — Platform Risk Eliminated Ahead of Trial

Moderna agreed on March 3 to pay up to $2.25 billion to settle patent disputes with Arbutus, Genevant (a Roivant subsidiary), and Roivant over lipid nanoparticle delivery technology used in Spikevax, six days before a jury trial was set to begin in Delaware federal court. The deal includes $950 million upfront (due July 2026) and an additional $1.3 billion contingent on an appellate ruling that Section 1498 does not shield Moderna as a government contractor (MedCity News). Moderna consented to a judgment of infringement and no invalidity on four Genevant/Arbutus patents, and received a global non-exclusive license to LNP technology specifically for SM-102-containing mRNA vaccines for infectious disease—not broader oncology or therapeutic applications. The license includes no future royalty obligations. Moderna shares rose approximately 16% on the news, per IPWatchdog; the company projects ending 2026 with $4.5–5 billion in cash.

Competitive implications: Pfizer and BioNTech face intensified litigation pressure following a favorable Markman ruling for Genevant in September 2025. Roivant, which holds the majority stake in Genevant, immediately expanded its share buyback program to $1 billion following the settlement; Arbutus is evaluating a return of capital to shareholders in Q3 2026. Leerink Partners analyst Mani Foroohar described Moderna's government contractor defense as "materially weaker" than the company suggested, per MedCity News. The settlement validates the commercial value of LNP IP: Moderna's roughly $48 billion in cumulative global vaccine sales produced a settlement representing less than 5% of total revenue, which analysts viewed as favorable. Companies developing alternative delivery technologies—lipid disc nanoparticles, polymer-based systems—may gain competitive positioning if traditional LNP licensing costs remain elevated.

Key risks: The settlement does not preclude future disputes over LNP patents held by other parties, and Moderna's non-COVID pipeline remains unproven clinically. If competing mRNA developers negotiate lower licensing fees, Moderna's multi-billion dollar payout could appear disadvantageous in retrospect.

Galderma Doubles Nemluvio Peak Sales Target to $4B — IL-31 MOA Gains Traction Against Dupixent

Galderma has raised its peak sales projection for Nemluvio (nemolizumab) to over $4 billion from a prior $2 billion estimate, as disclosed in its 2025 annual results on March 5. The IL-31 receptor antagonist posted $452 million in first-year sales across atopic dermatitis and prurigo nodularis, with the second half contributing $321 million as adoption accelerated. In the U.S., Nemluvio captured approximately 35% of new patient starts in prurigo nodularis and 8% in atopic dermatitis as of late January 2026, per CEO Flemming Ørnskov on the Q4 earnings call. Approximately 85% of commercially insured patients have first-line biologic coverage, and Galderma secured its first major Medicare access agreement in January 2026. Galderma now expects Nemluvio to break even in 2026, one year ahead of initial projections (FiercePharma). Jefferies raised its estimate to $4.2 billion following a physician survey showing expected Nemluvio use in 13% of first-line and 15% of second-line AD patients in five years.

Competitive implications: Sanofi and Regeneron face direct pressure in atopic dermatitis, where Dupixent holds dominant share but Nemluvio is capturing 8% of AD new starts in its first full year—and the trajectory is accelerating. If physicians confirm IL-31's superiority in pruritus-predominant phenotypes, Nemluvio could compress Dupixent's growth in dermatology even as Dupixent expands into COPD and other indications. Other dermatology-focused competitors may accelerate IL-31 or itch-targeted programs if Nemluvio's commercial traction validates the mechanism. The revised guidance also pressures Eli Lilly's oral JAK inhibitor franchise in atopic dermatitis, where oral convenience must now overcome both Dupixent's incumbency and Nemluvio's itch-focused differentiation.

Key risks: The $4 billion projection depends on sustained prescriber adoption and potential label expansions that Galderma has not publicly detailed. If real-world durability data or safety signals emerge that temper enthusiasm, the company may face challenges meeting the elevated guidance.

REGULATORY & APPROVALS

• FDA issued warning letters to 30 telehealth companies for false or misleading marketing claims about compounded GLP-1 products, targeting direct-to-consumer platforms operating while Novo Nordisk and Eli Lilly face supply constraints for branded semaglutide and tirzepatide.
• FDA agreed to hold a public hearing on Vanda's jet lag indication for Hetlioz (tasimelteon) following two Complete Response Letters since 2019, representing a rare escalation in FDA-sponsor dispute resolution that could set precedent for how companies challenge repeated regulatory setbacks.
• FDA approved Glenmark's fluticasone propionate inhalation aerosol, the first AB-rated generic of GSK's discontinued Flovent, ending Prasco Laboratories' sole-supplier position in the asthma inhaler generic market.
• PepGen disclosed a partial clinical hold on its phase 2 muscle wasting trial following FDA review of preclinical data, restricting new patient enrollment while allowing existing participants to continue dosing.

CLINICAL DATA

• Kyowa Kirin terminated its OX40 agonist program after two malignancies emerged, marking another setback for the costimulatory target class after Bristol Myers Squibb's 2023 withdrawal (Fierce Pharma).
• Zealand Pharma reported mean weight loss up to 10.7% at 42 weeks with its Roche-partnered amylin analog petrelintide in phase 2, emphasizing tolerability matching placebo levels as a potential differentiation versus GLP-1 agonists where GI side effects drive discontinuation rates above 20%.
• Pfizer appointed Jeff Legos to lead oncology R&D, charged with maximizing its $43 billion Seagen acquisition and advancing a PD-1xVEGF bispecific in-licensed from 3SBio toward 2028 readouts.

DEALS & PARTNERSHIPS

• Servier will acquire Day One Biopharmaceuticals for $2.5 billion, gaining Ojemda, an approved therapy for certain pediatric brain tumors, plus two clinical-stage oncology candidates.
• Lonza is divesting 60% of its capsules and health ingredients business to Lone Star Funds for $2.2 billion upfront, retaining a 40% minority position in a transaction valuing the full business at approximately $3 billion.
• Sanofi secured global rights to Sino Biopharm's dual JAK/ROCK inhibitor for up to $1.5 billion, adding a first-in-class mechanism to its immunology pipeline.
• UCB acquired global rights to an Antengene bispecific T-cell engager for up to $1.18 billion, expanding its immuno-oncology portfolio beyond existing neurology and immunology franchises while Antengene retains development and commercialization rights in Greater China.

BUSINESS & FINANCE

• Merck KGaA expects US revenue from MS therapy Mavenclad to cease after March 2026 following failed patent defense and anticipated generic launches.
• Bavarian Nordic CEO Paul Chaplin is departing after 27 years, including 12 as CEO, following the recent collapse of the company's proposed acquisition by a larger entity.
• Cognito Therapeutics closed an oversubscribed $105 million Series C to advance its neuromodulation device for Alzheimer's and other neurodegenerative diseases, now in late-stage development.
• Science closed a $230 million Series C to advance its brain-computer interface retinal implant technology, positioning the medtech to scale manufacturing and pursue regulatory clearance.
• Novo Nordisk is committing $506 million to expand its Ireland manufacturing site, addressing persistent supply constraints for its GLP-1 portfolio including Wegovy and Ozempic.

WHAT TO WATCH NEXT

Senate scrutiny of pharma MFN deals could shift voluntary pricing toward mandated disclosure

Senate Finance Committee Chair Ron Wyden is pressing 11 drugmakers to provide documentation demonstrating that their voluntary "most favored nation" pricing agreements with the Trump administration actually reduce costs for Medicaid programs (Fierce Pharma). The inquiry suggests skepticism about whether these voluntary commitments translate into enforceable rebates or net price reductions for state and federal payers. If voluntary agreements prove difficult to verify or enforce, the probe could foreshadow legislative or regulatory efforts to formalize pricing commitments through mandated disclosure or formal rebate structures. Companies that negotiated MFN terms face disclosure pressure, while those that declined such deals avoid immediate congressional scrutiny over Medicaid pass-through.

Kura-Syndax menin inhibitor formulary battle intensifies in NPM1-mutated AML

Kura Oncology reports certain insurance plans have granted preferred treatment status to its menin inhibitor, positioning the drug ahead of rival Syndax Pharmaceuticals' offering in acute myeloid leukemia (Endpoints News). Both companies have reported strong commercial launches in the NPM1-mutated AML segment, but formulary placement could prove decisive in a head-to-head market. The development highlights how formulary access is becoming a key battleground in oncology launches where multiple products enter within close timeframes. The scope and durability of these preferred statuses remain to be seen, and Syndax faces formulary pressure that could limit market access despite strong initial uptake.

Generic semaglutide cost analysis quantifies potential pricing floor for biosimilar competition

A new analysis estimates generic versions of Novo Nordisk's semaglutide products could be mass-produced for approximately $3 per patient per month, putting a sharp numerical bound on potential generic competition pricing. Current U.S. list prices for Wegovy and Ozempic exceed $900 per month, creating substantial headroom for generic margin compression. While patent exclusivity timelines remain the key gating factor for biosimilar entry, the analysis provides cost floor data that biosimilar developers including Lilly, Teva, and other generic manufacturers pursuing GLP-1 programs could reference in pricing strategies. Payers and PBMs gain leverage in formulary negotiations with data showing potential generic economics, though actual competitive threat depends on patent challenges and regulatory pathways potentially years away.